{"preliminary_commentary":{"by_channel":{"x_thread":2,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["pembrolizumab","AVD"],["pembrolizumab","escBEACOPP"]],"indication":"newly diagnosed classical Hodgkin lymphoma","name":"KEYNOTE-C11","nct_id":"NCT05008224","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=keynote-c11-nct05008224. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"KEYNOTE-C11","arms":[{"description":"After completing Positron Emission Tomography (PET) scan 1 during eligibility screening, participants received pembrolizumab monotherapy intravenous (IV) for three 3-week cycles followed by PET scan 2.\n\nParticipants next received 2 phases of chemotherapy. In chemotherapy phase 1, all participants received doxorubicin in combination with vinblastine \\& dacarbazine (AVD) IV for two 4-week cycles followed by PET scan 3. In chemotherapy phase 2, participants who were PET scan 3 negative, or positive and age ≥60 years, received up to 4 additional cycles of AVD IV, while participants who were PET scan 3 positive and age \\<60 years received up to four 3-week cycles of escalated bleomycin in combination with etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, \\& prednisone (escBEACOPP) IV.\n\nAll participants then received pembrolizumab consolidation IV for four 6-week cycles followed by a final PET scan.","label":"Pembrolizumab Monotherapy + AVD Chemotherapy/escBEACOPP Chemotherapy + Pembrolizumab Consolidation","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2024-05-26","type":"ACTUAL"},"conditions":["Classical Hodgkin Lymphoma"],"enrollment":{"count":146,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Pembrolizumab","otherNames":["MK-3475","SCH 900475","KEYTRUDA®"],"type":"BIOLOGICAL"},{"name":"Doxorubicin","otherNames":["Adriamycin","DOXIL®","Rubex®"],"type":"DRUG"},{"name":"Vinblastine","otherNames":["Alkaban-AQ®","Velban®"],"type":"DRUG"},{"name":"Dacarbazine","otherNames":["Dtic-Dome®"],"type":"DRUG"},{"name":"Bleomycin","otherNames":["Blenoxane®"],"type":"DRUG"},{"name":"Etoposide","otherNames":["Toposar®","VePesid®","Etopophos®","VP-16","Etoposide phosphate"],"type":"DRUG"},{"name":"Cyclophosphamide","otherNames":["Neosar®","Cytoxan®"],"type":"DRUG"},{"name":"Vincristine","otherNames":["Oncovin®","Vincasar PFS®"],"type":"DRUG"},{"name":"Procarbazine","otherNames":["Matulane®"],"type":"DRUG"},{"name":"Prednisone","otherNames":["Liquid Pred®","Meticorten®","Orasone®","Deltasone®"],"type":"DRUG"}],"last_update":"2025-06-06","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"Phase 2 Study of Pembrolizumab and Chemotherapy in Patients With Newly Diagnosed Classical Hodgkin Lymphoma (KEYNOTE-C11)","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2023-10-11","type":"ACTUAL"},"primary_outcomes":[{"measure":"Complete Response (CR) Rate at the End of Study Intervention as Assessed by Blinded Independent Central Review (BICR) Per Lugano 2014 Response Criteria","timeFrame":"Up to approximately 24 months"}],"references":[],"start_date":{"date":"2021-10-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)","url":"https://clinicaltrials.gov/study/NCT05008224"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/keynote-c11-nct05008224"}